SCHEMBL630140

SCHEMBL630140

CCOC(=O)CNc1cc2ccc(OCc3ccccc3)cc2cc1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
HSP90AA1 P07900 1/20 0.48
KMT2A Q03164 1/20 0.48
PPARG P37231 2/20 0.47
PPARD Q03181 1/20 0.47
PPARA Q07869 1/20 0.47
MAOB P27338 2/20 0.47
ALOX5 P09917 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LTA4H P09960 4/20 0.44
MRGPRX4 Q96LA9 1/20 0.43
SRD5A2 P31213 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
PPID Q08752 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2897343 0.87 SMN1; SMN2 (0.44) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL3003359 0.84 HDAC8 (0.48) PPARDMAOBALDH1A1NPC1MAPT
SCHEMBL22412427 0.81 HDAC8 (0.49) PPARDPPARAMAOBALDH1A1NPC1
SCHEMBL629377 0.79 LRRK2 (0.46) ALDH1A1LMNAL3MBTL1
SCHEMBL31277431 0.79 LRRK2 (0.46) ALDH1A1LMNAL3MBTL1
SCHEMBL4643473 0.79 LRRK2 (0.49) MEN1KMT2AALDH1A1LMNA
SCHEMBL5955117 0.78 ALDH1A1 (0.64) MEN1KMT2ANR1H4ALDH1A1LMNA
SCHEMBL16319339 0.77 GRK2 (0.55) MEN1KMT2AMAOBNR1H4ALDH1A1
SCHEMBL8104076 0.76 MRGPRX4 (0.50) MEN1KMT2AMAOBALDH1A1LMNA
SCHEMBL22412007 0.75 PTGER1 (0.47) MAOBALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963292-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-02-22 EP disclosed
US-7700633-B2 Organic compounds NOVARTIS AG (CH) 2010-04-20 US disclosed
US-20080262050-A1 Organic Compounds NOVARTIS AG (CH) 2008-10-23 US disclosed
EP-1963292-A2 ORGANIC COMPOUNDS Novartis Pharma AG (CH) 2008-09-03 EP disclosed
WO-2007067615-A2 THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262050-A1 Organic Compounds PTPRS, PTPRO, PTPRC MEN1 4331/4885HSP90AA1 2838/4885KMT2A 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.